Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...

Results of the first human study of a capsule designed to replace injections of biologics have been announced, using an automatic pill designed by Silicon Valley-based Rani Therapeutics.

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have been given an average rating of “Buy” by the seven brokerages that are covering the stock, Marketbeat.com reports.

Rani Therapeutics Holdings, Inc. (RANI) stock price is 1.43 and Rani Therapeutics Holdings, Inc. (RANI) 10-day simple moving average is 1.36. Rani Therapeutics Holdings, Inc. (RANI) stock price is ...

- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting ...